Examining The Emergence Of Unit- & Bi-Dose Nasal Sprays

Molecules that are limited by a slow onset of action, a suboptimal side-effect profile, or a complicated administration process, may be good candidates for adaptation to a unit- or bi-dose nasal delivery format. This is especially true for drugs targeting the central nervous system (CNS). Established molecules may also benefit from shorter development timelines and regulatory review cycles.

Nasal spray administration of medicine offers advantages over oral and intravenous (IV) delivery. Catalent’s Mark Ignaczak, David Wilcox, and Tom Clark discuss the advantages and opportunities of adopting unit- and bi-dose nasal delivery technology.